Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2014 | ASH 2014: The management of CLL

George Follows • 9 Apr 2015
ASH 2014
Chronic Lymphocytic Leukemia

Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularity defined subtypes in CLL.

More from George Follows

Five-year follow up of the UK CLL Forum ibrutinib data 3:58
Five-year follow up of the UK CLL Forum ibrutinib data
George Follows • 20 Sep 2019
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse 1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
PEP-C for treatment of relapsed/refractory lymphoma 1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
MURANO study: exciting times in CLL 2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals